" class="no-js "lang="en-US"> ReviR Therapeutics - Medtech Alert
Tuesday, September 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ReviR Therapeutics | Pharmtech Focus

ReviR Therapeutics

About ReviR Therapeutics

ReviR Therapeutics

Building a Scalable Platform addressing unmet therapeutic needs by REVIsing RNA with Small Molecules

Related Story

News

 ReviR Therapeutics and Asieris Pharmaceuticals Enter Agreement | MTA

ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics

February 8 2023

ReviR Therapeutics, a privately held developer of a suite of small molecule RNA-targeting technologies for […]

Appointments

 ReviR Therapeutics Appoints Paul August

ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer

July 4 2022

ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment […]

News

 ReviR Therapeutics Raises ~$20M in Pre-A Financing | Pharmtech Focus

ReviR Therapeutics Raises ~$20M in Pre-A Financing

January 18 2022

ReviR Therapeutics, a South San Francisco based biopharmaceutical company, completed a Pre-A financing round with ~$20M. The funds […]